Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by DekaBank Deutsche Girozentrale

0
200
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by DekaBank Deutsche Girozentrale



DekaBank Deutsche Girozentrale cut its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) by 7.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,100 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Revance Therapeutics were worth $507,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new position in shares of Revance Therapeutics in the fourth quarter worth $30,000. Commonwealth Equity Services LLC grew its stake in shares of Revance Therapeutics by 16.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 24,715 shares of the biopharmaceutical company’s stock worth $403,000 after purchasing an additional 3,555 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Revance Therapeutics in the fourth quarter worth $1,940,000. Duality Advisers LP bought a new position in shares of Revance Therapeutics in the fourth quarter worth $527,000. Finally, Perfromance Wealth Partners LLC bought a new position in shares of Revance Therapeutics in the fourth quarter worth $212,000. 79.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Revance Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Revance Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $23.60.

Revance Therapeutics Trading Down 6.3 %

Shares of RVNC stock opened at $15.65 on Friday. The stock has a 50-day simple moving average of $14.01 and a 200 day simple moving average of $15.24. Revance Therapeutics, Inc. has a fifty-two week low of $11.27 and a fifty-two week high of $30.57. The stock has a market capitalization of $1.14 billion, a P/E ratio of -3.87 and a beta of 1.00. The company has a quick ratio of 3.87, a current ratio of 4.01 and a debt-to-equity ratio of 14.80.

Revance Therapeutics (NASDAQ:RVNC – Get Rating) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.03). Revance Therapeutics had a negative net margin of 305.27% and a negative return on equity of 273.73%. The firm had revenue of $25.26 million for the quarter, compared to the consensus estimate of $23.55 million. On average, sell-side analysts expect that Revance Therapeutics, Inc. will post -3.97 earnings per share for the current fiscal year.

Revance Therapeutics Company Profile

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Featured Stories

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)



Receive News & Ratings for Revance Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revance Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link